Scientists around the world do a lot of work, and the improvement in communications helped them reach out to their colleagues from the other side of the globe. The introduction of the internet also helped them to deliver information instantly, and it is helpful for those who are working in the field of medicine. Scientists keep on doing experiments day and night to discover breakthroughs, including the treatment and cure for fatal diseases, and the introduction of Oncotarget was a big help for them. Oncotarget is the only peer-reviewed online medical journal that was created by Mr. Andrei V. Gudkov and Mr. Blagosklonny, two of the most brilliant oncologists working at the Roswell Park Cancer Institute. Mr. Gudkov and Mr. Blagosklonny knew that the scientists would need a platform where they can share their discoveries, so the two decided to create Oncotarget and agreed that the platform should be online for easier access and sharing. Follow Oncotarget on Twitter.
Presently, the online medical journal releases two articles per week, and each article would go under extreme and strict reviews from individuals who are affiliated with the scientific community. Each article will be reviewed in detail, making sure that all the information is accurate and correct. After the review, it will be uploaded online for the scientists, and even the public, to see. Oncotarget has reached a global audience, and they are now considered as the most extensive online medical journal. Oncotarget initially focused on cancer-related information, but today, they are also including all information about rare and fatal diseases, publishing them for the use of the scientists.
Learn more: https://www.ncbi.nlm.nih.gov/pmc/journals/1558/
Mikhail Blagosklonny and Andrei V. Gudkov are proud of their accomplishment, and they announced that Oncotarget would receive periodical updates to cater the needs of its users. Mikhail Blagosklonny and Andrei V. Gudkov stated that the online medical journal is the future of medicine, and they are hoping that with the introduction of the platform, more scientists will be able to share information with one another, and more diseases can be eradicated in the future because of the free flow of information. They are also hoping that Oncotarget will keep its present stature for years to come. Visit Oncotarget’s profile page at facebook.com